Acrobiosystems Files for Hong Kong IPO as Life Science Tools Leader
Acrobiosystems Co., Ltd. made its initial public offering filing to the Hong Kong Stock Exchange,...
Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline
Shanghai Aucta Pharmaceuticals Co., Ltd. made its initial public offering (IPO) filing to the Hong...
Bio-heart Secures Indonesia Approval for Iberis RDN System
Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced market approval in Indonesia for its...
BioArctic Partner Eisai Submits EMA Application for Four-Week Lecanemab Dosing in Alzheimer’s
BioArctic AB (OTCMKTS: BRCTF) partner Eisai (TYO: 4523) announced submission of a proposed Marketing Authorisation Variation...
Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy
Nuance Pharma announced that its market filing for Ohtuvayre (ensifentrine) as maintenance treatment for patients...
ASCP Launches $250K Grants for mCRC Biomarker Testing with Pfizer, ASCO
The American Society for Clinical Pathology (ASCP), in collaboration with Pfizer (NYSE: PFE) and with participation...
Boehringer Ingelheim Licenses Simcere’s SIM0709 Bispecific for Inflammatory Bowel Disease
Boehringer Ingelheim and Simcere Pharmaceutical Group (HKG: 2096) announced a licensing and collaboration agreement to...
Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency
Visen Pharmaceuticals (HKG: 2561), a joint venture between Ascendis Pharma (Denmark) and Vivo Capital, announced...
Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture
Sunshine Lake Pharma Co., Ltd. (HKG: 6887) and Xtalpi Inc. (HKG: 2228) announced plans to...
HanchorBio Partners with WuXi Biologics on Next‑Gen Fusion Protein Manufacturing
HanchorBio, Inc. and WuXi Biologics (HKG: 2269) announced a strategic collaboration under which WuXi Biologics will...
Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30
Ascletis Pharma Inc. (HKG: 1672) announced that the first patient has been dosed in a 13‑week...
Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform
Knature Biopharmaceutical Co., Ltd. announced it has filed for an initial public offering (IPO) with...
Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge
Sanofi (NASDAQ: SNY) announced positive results from two global Phase III studies (SHORE and COAST 2) for amlitelimab,...
MicroPort Endovascular’s Talos Stent Graft Secures EU CE MDR Certification
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) announced that its Talos straight thoracic aortic...
Huahui Health’s Libevitug Wins NMPA Approval as World’s First HDV Antibody Therapy
Huahui Health announced that China’s National Medical Products Administration (NMPA) has granted conditional approval for...
GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing
GenEditBio announced a joint development agreement with uBriGene Biosciences International Co. to advance next‑generation lipid...
AstraZeneca’s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis
AstraZeneca plc (AZ, NASDAQ: AZN) announced that China’s National Medical Products Administration (NMPA) has approved Soliris...
Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute
Merck & Co. Inc. (MSD, NYSE: MRK) has reportedly ended acquisition talks with Revolution Medicines after the...
Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets
Dizal Pharmaceutical Co., Ltd. (SHA: 688192), the China‑based joint venture established by AstraZeneca (AZ, NASDAQ: AZN)...
Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that China’s National Medical Products Administration (NMPA)...